Abstract

Objective To study the effect on body mass index(BMI)caused by treatment with Gonadotropin-releasing hormone analogs(GnRHa)in girls with central precocious puberty(CPP)or early and fast puberty(EFP). Methods The BMI in 318 girls(227 CPP and 91 EFP)treated with GnRHa alone was analyzed. Among them 89 were followed up to their final adult height. Results Before GnRHa treatment was started, the girls with CPP and EFP had a mean BMI standard deviation score(SDS)for chronological age(BMISDSCA)of 0.39±0.84 and for bone age(BMISDSBA)of -0.11±0.69. At the end of treatment, the mean BMISDSCA was 0.59±1.01 and BMISDSBA was 0.24±0.89, both were significantly higher than those at initiation. The increment in BMISDSBA(0.38±0.50)was greater than that in BMISDSCA(0.21±0.56). Moreover, the ratio of overweight(BMI>85%)was significantly elevated. BMISDSCA of 89 girls who were visited at their final adult height was 0.17±1.15, which was similar with BMISDS at initiation and in normal population. Conclusion The mean BMISDSCA of CPP and EFP was significantly higher than the general population, while BMISDSBA was significantly lower. During GnRHa treatment, BMISDS tended to be elevated. But it was reversible, for the mean BMISDS was back to normal at final adult height. (Chin J Endocrinol Metab, 2015, 31: 690-695) Key words: Central precocious puberty; Early and fast puberty; Gonadotropin-releasing hormone analogs; Body mass index

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.